Sensitivity and specificity of diffusion-weighted magnetic resonance imaging in diagnosis of bladder cancers

Clinical and Investigative Medicine

Volumn 38, Issue 4, 2015, Pages E173-E184

  Zhai, Ning ^a   Wang, Yan Hui ^a   Zhu, Lai Ming ^a   Wang, Jie Huan ^a   Sun, Xin Hai ^a   Hu, Xi Bin ^a   Li, Xian ^a   Yu, Tao ^a   Wang, Xin Ling ^a   Meng, Nan ^a   Yan, Qi Chang ^a   Li, Xue Jiao ^a   Luo, Ya Hong ^a  

^a JINING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER; DIFFUSION WEIGHTED IMAGING; HUMAN; META ANALYSIS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84939128909     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Draga ROP, Grimbergen MCM, Vijverberg PLM, van Swol CFP, Jonges TGN, Kummer JA, Bosch JLR. In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. Anal Chem 2010;82(14):5993-9.
2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737-45.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
4. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 2010;193(2):131-7.
5. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: From tumor development to patient's death. World J Urol 2007;25(3):285-95.
6. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
7. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009;56(3):430-42.
8. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhausser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Bruning T, Stenzl A, UroScreen Study G. Nuclear matrix protein-22: A prospective evaluation in a population at risk for bladder cancer. Results from the uroscreen study. BJU Int 2012;110(5):699-708.
9. Avcu S, Koseoglu MN, Ceylan K, Bulut MD, Unal O. The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions. Br J Radiol 2011;84(1006):875-82.
10. Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, Van Cutsem E, Filip C, Haustermans K. Value of diffusionweighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: Preliminary results. Int J Radiat Oncol Biol Phys 2012;82(2):863-70.
11. Li XR, Cheng LQ, Liu M, Zhang YJ, Wang JD, Zhang AL, Song X, Li J, Zheng YQ, Liu L. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 2012;29(2):425-31.
12. Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y. Urinary bladder cancer: Diffusion-weighted mr imaging--accuracy for diagnosing t stage and estimating histologic grade. Radiology 2009;251(1):112-21.
13. El-Assmy A, Abou-El-Ghar ME, Mosbah A, El-Nahas AR, Refaie HF, Hekal IA, El-Diasty T, Ibrahiem el H. Bladder tumour staging: Comparison of diffusion- and t2-weighted mr imaging. Eur Radiol 2009;19(7):1575-81.
14. Rosenkrantz AB, Mussi TC, Melamed J, Taneja SS, Huang WC. Bladder cancer: Utility of MRI in detection of occult muscleinvasive disease. Acta Radiol 2012;53(6):695-9.
15. Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Diffusion-weighted MRI in bladder carcinoma: The differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014;39(1):135-41.
16. Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: A critical analysis of the literature. Eur Urol 2012;61(2):326-40.
17. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, Group EGW. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3(iii40-8).
18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q-. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-36.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
20. Yang X, Guo Y, Du Y, Yang J, Li S, Liu S, Li K, Zhang D. Serum microrna-21 as a diagnostic marker for lung carcinoma: A systematic review and meta-analysis. PLoS One 2014;9(5):e97460.
21. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008;27(5):625-50.
22. Kobayashi S, Koga F, Yoshida S, Masuda H, Ishii C, Tanaka H, Komai Y, Yokoyama M, Saito K, Fujii Y, Kawakami S, Kihara K. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: Potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011;21(10):2178-86.
23. Zhou GX, Sheng L, Zhao JM, Wang W, Wang RB, Zong GL, Wang B, He N. Diagnostic value of diffusion weighted imaging in T stage of bladder cancer by 3.0T MR. Journal of Clinical Radiology 2011(05):681-84.
24. Kang XC, Di R, Feng XJ, Feng GS. The value of MR diffusionweighted imaging in the differential diagnosis of urinary bladder lesions. Journal of China Clinic Medical Imaging 2012(05):331-34.
25. Papalia R, Simone G, Grasso R, Augelli R, Faiella E, Guaglianone S, Cazzato R, Del Vescovo R, Ferriero M, Zobel B, Gallucci M. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: Detection rate of pelvic lymph node metastases. BJU Int 2012;109(7):1031-6.
26. Zhang LH, Zhu YJ, Bo JJ, Liu DM, Huang YR. The role of diffusion-weighted MR imaging in diagnosis of bladder cancer. Tumor 2012;32(12):1025-29.
27. Lista F, Andres G, Caceres F, Ramon de Fata F, Rodriguez- Barbero JM, Angulo JC. Evaluation of risk of muscle invasion, perivesical and/or lymph node affectation by diffusion-weighted magnetic nuclear resonance in the patient who is a candidate for radical cystectomy. Actas Urol Esp 2013;37(7):419-24.
28. Wu LM, Chen XX, Xu JR, Zhang XF, Suo ST, Yao QY, Fan Y, Hu J. Clinical value of T2-weighted imaging combined with diffusion-weighted imaging in preoperative T staging of urinary bladder cancer: A large-scale, multiobserver prospective study on 3.0-T MRI. Acad Radiol 2013;20(8):939-46.
29. Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, Shariat SF, Szarvas T, Baltzer PA. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol 2014
30. Suo ST, Chen XX, Fan Y, Wu LM, Yao QY, Cao MQ, Liu Q, Xu JR. Histogram analysis of apparent diffusion coefficient at 3.0 T in urinary bladder lesions: Correlation with pathologic findings. Acad Radiol 2014;21(8):1027-34.
31. Zhou G, Chen X, Zhang J, Zhu J, Zong G, Wang Z. Contrastenhanced dynamic and diffusion-weighted MR imaging at 3.0 T to assess aggressiveness of bladder cancer. Eur J Radiol 2014;83(11):2013-8.
32. Vargas HA, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H, Bochner BH. Prospective evaluation of MRI, (1)(1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012;81(12):4131-7.
33. Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted mri. J Magn Reson Imaging 2010;31(3):562-70.
34. Yoshida S, Koga F, Kobayashi S, Tanaka H, Satoh S, Fujii Y, Kihara K. Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. World J Radiol. 2014;6(6):344-54.
35. Yoshida S, Masuda H, Ishii C, Tanaka H, Fujii Y, Kawakami S, Kihara K. Usefulness of diffusion-weighted MRI in diagnosis of upper urinary tract cancer. AJR Am J Roentgenol 2011;196(1):110-6.
36. Yamada Y, Kobayashi S, Isoshima S, Arima K, Sakuma H, Sugimura Y. The usefulness of diffusion-weighted magnetic resonance imaging in bladder cancer staging and functional analysis. J Cancer Res Ther. 2014;10(4):878-82.
37. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci. 2005;4(1):35-42.
38. Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012;83(1):e21-7.